Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer

NCT01352208 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01352208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01352208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2011
Completion date
September 30, 2012
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer